Citas bibligráficas
Esta es una referencia generada automáticamente. Modifíquela de ser necesario
Ruiz, J., (2021). Neuroprotección con eritropoyetina en recién nacidos prematuros [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/7815
Ruiz, J., Neuroprotección con eritropoyetina en recién nacidos prematuros [Tesis]. PE: Universidad Privada Antenor Orrego; 2021. https://hdl.handle.net/20.500.12759/7815
@misc{renati/372920,
title = "Neuroprotección con eritropoyetina en recién nacidos prematuros",
author = "Ruiz Lijap, José Luis",
publisher = "Universidad Privada Antenor Orrego",
year = "2021"
}
Título: Neuroprotección con eritropoyetina en recién nacidos prematuros
Autor(es): Ruiz Lijap, José Luis
Asesor(es): Tapia Zerpa, Jorge Luis
Palabras clave: Prematuro; Encefalopatía
Campo OCDE: https://purl.org/pe-repo/ocde/ford#3.02.27
Fecha de publicación: 2021
Institución: Universidad Privada Antenor Orrego
Resumen: La prematuridad, es la primera causa de mortalidad en niños menores de 5 años a nivel
mundial. Además, corren el riesgo de desarrollar alteraciones neurológicas como la encefalopatía
del prematuro y el retraso en el desarrollo neurológico a largo plazo que conlleva un problema
de salud muy alto. En la actualidad, se ha investigado bastante sobre tratamientos que ayuden
a disminuir el riesgo de las variables mencionadas. Uno de ellos y de los más prometedores, es
la eritropoyetina como neuroprotector en nacidos prematuros, debido a que esta hormona
endógena se encuentra en mínimas concentraciones durante el desarrollo fetal. Asimismo, en el
sistema nervioso central, la eritropoyetina se asocia a funciones no hematopoyéticas que
guardan relación con la neuroprotección y que el uso de tratamiento exógeno produciría muchos
beneficios como la disminución del efecto dañino del glutamato y el óxido nítrico; la inhibición de
factores asociados con la apoptosis neuronal y los efectos antioxidantes en las mismas células.
Prematurity is the leading cause of mortality in children under 5 years of age worldwide. In addition, they are at risk of developing neurological disorders such as encephalopathy of prematurity and long-term delay in neurodevelopment that leads to a very high health problem. Currently, there has been a lot of research on treatments that help reduce the risk of the mentioned variables. One of them, and one of the most promising, is erythropoietin as a neuroprotectant in premature births, since this endogenous hormone is found in minimal concentrations during fetal development. Likewise, in the central nervous system, erythropoietin is associated with non-hematopoietic functions that are related to neuroprotection and that the use of exogenous treatment would produce many benefits such as reducing the harmful effect of glutamate and nitric oxide; the inhibition of factors associated with neuronal apoptosis and the antioxidant effects in the same cells.
Prematurity is the leading cause of mortality in children under 5 years of age worldwide. In addition, they are at risk of developing neurological disorders such as encephalopathy of prematurity and long-term delay in neurodevelopment that leads to a very high health problem. Currently, there has been a lot of research on treatments that help reduce the risk of the mentioned variables. One of them, and one of the most promising, is erythropoietin as a neuroprotectant in premature births, since this endogenous hormone is found in minimal concentrations during fetal development. Likewise, in the central nervous system, erythropoietin is associated with non-hematopoietic functions that are related to neuroprotection and that the use of exogenous treatment would produce many benefits such as reducing the harmful effect of glutamate and nitric oxide; the inhibition of factors associated with neuronal apoptosis and the antioxidant effects in the same cells.
Enlace al repositorio: https://hdl.handle.net/20.500.12759/7815
Disciplina académico-profesional: Medicina Humana
Institución que otorga el grado o título: Universidad Privada Antenor Orrego. Facultad de Medicina Humana
Grado o título: Médico Cirujano
Jurado: Kawano Kobashigawa, Jorge Eduardo; Cisneros Infantas, Luz Herlinda; Salcedo Espejo, Elena Ysabel
Fecha de registro: 29-jul-2021
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons